Brookline Capital Markets Estimates Moderna FY2029 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Equities researchers at Brookline Capital Markets reduced their FY2029 EPS estimates for shares of Moderna in a research report issued on Monday, August 31st. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings per share of $11.54 for the year, down from their prior forecast of $11.69. Brookline Capital Markets currently has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($6.11) per share. Brookline Capital Markets also issued estimates for Moderna’s FY2030 earnings at $19.11 EPS.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.13) EPS.

Several other equities research analysts have also issued reports on the company. Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research note on Friday. CLSA raised Moderna to an “outperform” rating in a research report on Friday. Bradesco Corretora upgraded Moderna to an “outperform” rating in a report on Friday. Bank of America upgraded Moderna from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 19th. Finally, JPMorgan Chase & Co. raised their price target on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. Seven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Moderna has an average rating of “Hold” and a consensus price target of $80.53.

Moderna Trading Up 1.7%

Shares of NASDAQ MRNA opened at $140.34 on Tuesday. The business’s 50 day moving average is $78.73 and its two-hundred day moving average is $60.54. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna has a 1-year low of $22.28 and a 1-year high of $176.66. The stock has a market capitalization of $56.03 billion, a P/E ratio of -17.56 and a beta of 0.91.

Hedge Funds Weigh In On Moderna

Several hedge funds have recently bought and sold shares of MRNA. Louisiana State Employees Retirement System purchased a new position in Moderna in the 1st quarter worth about $899,000. Merck & Co. Inc. purchased a new stake in Moderna in the 2nd quarter valued at about $161,642,545. Bank of New York Mellon Corp purchased a new stake in Moderna in the 2nd quarter valued at about $119,168,000. Contravisory Investment Management Inc. grew its stake in Moderna by 1,387.6% in the 2nd quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock worth $1,696,000 after acquiring an additional 22,590 shares in the last quarter. Finally, Lingotto Investment Management LLP grew its stake in Moderna by 33.7% in the 4th quarter. Lingotto Investment Management LLP now owns 498,693 shares of the company’s stock worth $14,706,000 after acquiring an additional 125,598 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the sale, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.80% of the company’s stock.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported encouraging results from their cancer-vaccine collaboration, supporting Moderna’s strategy to expand beyond COVID-19 vaccines into personalized oncology treatments. The results have attracted positive attention from market commentator Jim Cramer and helped drive investor enthusiasm. Jim Cramer Called Moderna Inc. and Merck’s Trial Results Encouraging
• Positive Sentiment: Recent clinical evidence has provided a major boost to the broader mRNA sector after a difficult period for the technology. Coverage highlights the potential medical and commercial significance of Moderna’s cancer-vaccine work, particularly as the company seeks to establish growth drivers beyond respiratory vaccines. After a Rough Stretch, mRNA Gets a Boost
• Positive Sentiment: Moderna received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines targeting the latest SARS-CoV-2 subvariant, as well as mFlusiva, its first mRNA influenza vaccine for adults aged 50 and older. The approvals broaden its respiratory portfolio and could improve the company’s long-term commercial opportunity in seasonal vaccines. What Do Moderna FDA Vaccine Approvals Mean for Its Respiratory Push?
• Positive Sentiment: Argus upgraded Moderna to “Buy,” adding a more bullish analyst view following the company’s clinical and regulatory developments. Argus Upgrades Moderna to Buy
• Neutral Sentiment: Trading volume increased significantly after the analyst upgrade, indicating heightened investor interest and strong momentum in MRNA shares. However, heavy activity can also reflect short-term speculation following the stock’s steep rally. Moderna Sees Large Volume Increase After Analyst Upgrade
• Negative Sentiment: Analysts overall maintain an average “Hold” rating, signaling that Wall Street remains cautious despite the recent clinical progress. The stock’s rapid appreciation has also raised concerns about valuation and the risk of profit-taking if additional trial results do not meet high expectations. Moderna Receives Average Rating of Hold

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.